$RYTM Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.61 up 25.61% YoY
• Reported revenue of $92.13M up 79.59% YoY
• For 2026, Rhythm Pharmaceuticals anticipates approximately $360M to $380M in Non-GAAP Operating Expenses, including R&D expenses of approximately $165M to $175M and SG&A expenses of approximately $195M to $205M.